Antibody targeting of B-cell maturation antigen on malignant plasma cells
Open Access
- 1 November 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (11) , 3009-3018
Abstract
B-cell maturation antigen (BCMA) is expressed on normal and malignant plasma cells and represents a potential target for therapeutic intervention. BCMA binds to two ligands that promote tumor cell survival, a proliferation inducing ligand (APRIL) and B-cell activating factor. To selectively target BCMA for plasma cell malignancies, we developed antibodies with ligand blocking activity that could promote cytotoxicity of multiple myeloma (MM) cell lines as naked antibodies or as antibody-drug conjugates. We show that SG1, an inhibitory BCMA antibody, blocks APRIL–dependent activation of nuclear factor-κB in a dose-dependent manner in vitro. Cytotoxicity of SG1 was assessed as a naked antibody after chimerization with and without Fc mutations that enhance FcγRIIIA binding. The Fc mutations increased the antibody-dependent cell-mediated cytotoxicity potency of BCMA antibodies against MM lines by ∼100-fold with a ≥2-fold increase in maximal lysis. As an alternative therapeutic strategy, anti-BCMA antibodies were endowed with direct cytotoxic activity by conjugation to the cytotoxic drug, monomethyl auristatin F. The most potent BCMA antibody-drug conjugate displayed IC50 values of ≤130 pmol/L for three different MM lines. Hence, BCMA antibodies show cytotoxic activity both as naked IgG and as drug conjugates and warrant further evaluation as therapeutic candidates for plasma cell malignancies. [Mol Cancer Ther 2007;6(11):3009–18]Keywords
This publication has 49 references indexed in Scilit:
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMAMolecular Cancer Therapeutics, 2007
- Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRILBlood, 2006
- CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.Clinical Cancer Research, 2006
- Cancer immunity hits multiple myelomaBlood, 2005
- Identification of proteoglycans as the APRIL-specific binding partnersJournal of Experimental Medicine, 2005
- Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferationCell Death & Differentiation, 2005
- Human B Lymphocyte Malignancies: Exploitation of BLyS and APRIL and Their Receptors2004
- Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragmentsTissue Antigens, 1996